Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Verastem, Inc.
Servier
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
National Cancer Institute (NCI)
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Hoosier Cancer Research Network
Cancer Research UK
Turning Point Therapeutics, Inc.
Obsidian Therapeutics, Inc.
Shanxi Province Cancer Hospital
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Frontier Medicines Corporation
Bristol-Myers Squibb
Filamon LTD
PMV Pharmaceuticals, Inc
Mayo Clinic
Jonsson Comprehensive Cancer Center
Revolution Medicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A2 Biotherapeutics Inc.
Avenzo Therapeutics, Inc.
Providence Health & Services
M.D. Anderson Cancer Center
Essen Biotech
Jonsson Comprehensive Cancer Center
Stanford University
Revolution Medicines, Inc.
Incyte Corporation
St. Joseph's Healthcare Hamilton
Auricula Biosciences Inc.
Grey Wolf Therapeutics
VA Office of Research and Development
University of Nebraska
Xemed LLC
Kidney Cancer Research Bureau
3H Pharmaceuticals Co., Ltd.
Big Ten Cancer Research Consortium
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center